0.23
-0.0048(-2.04%)
Currency In USD
Address
260 Sheridan Avenue
Palo Alto, CA 94306
United States of America
Phone
650 800 6676
Website
Sector
Healthcare
Industry
Biotechnology
Employees
42
First IPO Date
May 27, 2020
| Name | Title | Pay | Year Born |
| Dr. Hans-Georg Lerchen Ph.D. | Chief Scientific Officer | 0 | N/A |
| Dr. Beatrix Stelte-Ludwig Ph.D. | Executive Chief Development Officer | 0 | N/A |
| Mr. Steven H. Bloom R.Ph. | Chief Business Officer | 0 | 1961 |
| Ms. Karen Quarford M.B.A. | Vice President of Quality Operations & Compliance | 0 | N/A |
| Dr. Raj Dua MBA, Ph.D. | Vice President of Biologics Development and Manufacturing and Senior VP of Chemistry & Manufacturing | 0 | N/A |
| Ms. Gabriela Jairala | Vice President of Investor Relations & Corporate Communications and Chief of Staff | 0 | N/A |
| Ms. Melissa Merrick SPHR | Senior Director of People & Culture and Head of Human Resource | 0 | N/A |
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.